Rombaldi Renato L, Serafini Eduardo P, Mandelli Jovana, Zimmermann Edineia, Losquiavo Kamille P
Diagnosis - Molecular Laboratory, University of Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil.
Virol J. 2009 Jun 21;6:83. doi: 10.1186/1743-422X-6-83.
The purpose was to study the perinatal transmission of human papillomavirus DNA (HPV-DNA) in 63 mother-newborn pairs, besides looking at the epidemiological factors involved in the viral DNA transmission. The following sampling methods were used: (1) in the pregnant woman, when was recruited, in cervix and clinical lesions of the vagina, vulva and perineal region; (2) in the newborn, (a) buccal, axillary and inguinal regions; (b) nasopharyngeal aspirate, and (c) cord blood; (3) in the children, buccal was repeated in the 4th week and 6th and 12th month of life. HPV-DNA was identified using two methodologies: multiplex PCR (PGMY09 and MY11 primers) and nested-PCR (genotypes 6/11, 16, 18, 31, 33, 42, 52 and 58). Perinatal transmission was considered when concordance was found in type-specific HPV between mother/newborn or mother/child. HPV-DNA genital was detected in 49 pregnant women submitted to delivery. Eleven newborns (22.4%, n = 11/49) were HPV-DNA positive. In 8 cases (16.3%, n = 8/49) there was type specific HPV concordance between mother/newborn samples. At the end of the first month of life three children (6.1%, n = 3/49) became HPV-DNA positive, while two remained positive from birth. In 3 cases (100%, n = 3/3) there was type specific HPV concordance between mother/newborn samples. In the 6th month, a child (2%, n = 1/49) had become HPV-DNA positive between the 1st and 6th month of life, and there was type specific HPV concordance of mother/newborn samples. All the HPV-DNA positive children (22.4%, n = 11/49) at birth and at the end first month of life (6.1%, n = 3/49) became HPV-DNA negative at the age of 6 months. The HPV-DNA positive child (2%, n = 1/49) from 1st to the 6th month of life became HPV-DNA negative between the 6th and 12th month of life and one child had anogenital warts. In the twelfth month all (100%, n = 49/49) the children studied were HPV-DNA negative. A positive and significant correlation was observed between perinatal transmission of HPV-DNA and the immunodepression of maternal variables (HIV, p = 0.007). Finally, the study suggests that perinatal transmission of HPV-DNA occurred in 24.5% (n = 12/49) of the cases studied.
本研究旨在对63对母婴进行人乳头瘤病毒DNA（HPV-DNA）围产期传播的研究，并观察病毒DNA传播的相关流行病学因素。采用以下采样方法：（1）孕妇入组时，采集宫颈、阴道、外阴及会阴区域的临床病变样本；（2）新生儿采集（a）颊部、腋窝及腹股沟区域样本；（b）鼻咽抽吸物；（c）脐带血样本；（3）儿童在出生后第4周、6个月和12个月时重复采集颊部样本。采用两种方法鉴定HPV-DNA：多重聚合酶链反应（PGMY09和MY11引物）和巢式聚合酶链反应（基因型6/11、16、18、31、33、42、52和58）。当母亲/新生儿或母亲/儿童之间的HPV型特异性一致时，认为存在围产期传播。49例分娩的孕妇检测到HPV-DNA生殖器感染。11例新生儿（22.4%，n = 11/49）HPV-DNA阳性。8例（16.3%，n = 8/49）母亲/新生儿样本间存在HPV型特异性一致。出生后第一个月末，3例儿童（6.1%，n = 3/49）HPV-DNA转为阳性，2例自出生起一直阳性。3例（100%，n = 3/3）母亲/新生儿样本间存在HPV型特异性一致。6个月时，1例儿童（2%，n = 1/49）在出生后第1至6个月期间HPV-DNA转为阳性，且母亲/新生儿样本间存在HPV型特异性一致。所有出生时及出生后第一个月末HPV-DNA阳性的儿童（22.4%，n = 11/49和6.1%，n = 3/49）在6个月龄时HPV-DNA转为阴性。出生后第1至6个月HPV-DNA阳性的1例儿童（2%，n = 1/49）在6至12个月期间HPV-DNA转为阴性，1例儿童患有肛门生殖器疣。12个月时，所有研究儿童（100%，n = 49/49）HPV-DNA均为阴性。观察到HPV-DNA围产期传播与母亲免疫抑制变量（HIV，p = 0.007）之间存在显著正相关。最后，研究表明在24.5%（n = 12/49）的研究病例中发生了HPV-DNA围产期传播。
